Gesynta Pharma AB

Gesynta Pharma AB is a Swedish clinical-stage biopharmaceutical company focused on developing first-in-class oral therapies for chronic inflammatory diseases. The company's research is centered on the enzyme microsomal prostaglandin E synthase-1 (mPGES-1), a key driver of inflammation and pain. By selectively inhibiting this enzyme, Gesynta aims to provide potent anti-inflammatory and pain-relieving effects without the side effects associated with traditional NSAIDs or hormonal treatments. Originally spun out from research at the Karolinska Institutet, the company has pivoted its lead candidate, vipoglanstat, from systemic sclerosis to endometriosis following Phase 2 exploratory data. The company is currently advancing a pipeline of small molecule inhibitors targeting high unmet needs in women's health and chronic pain management.